Back to Newsroom
Back to Newsroom

Hemogenyx Pharmaceuticals PLC Announces CDX Patent Application

Friday, 12 July 2019 02:00 AM

Hemogenyx Pharmaceuticals PLC

LONDON, UK / ACCESSWIRE / July 12, 2019 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has filed a new patent covering:

  • a method of application of bi-specific antibodies ("CDX") for conditioning patients for bone marrow transplantation
  • composition matter (sequences) of newly-discovered monoclonal antibodies against a target protein expressed on the surface of hematopoietic stem cells/hematopoietic progenitors and a number of leukemias, such as acute myeloid leukemia ("AML")

Dr Vladislav Sandler, Chief Executive Officer, commented, "Filing this patent is an important development and further solidifies Hemogenyx's leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others. The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor."

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.


Hemogenyx Pharmaceuticals plc

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

[email protected]

Sir Marc Feldmann, Chairman

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey

US Media enquiries

Tel: +1 (323) 646-3249

Lowell Goodman

[email protected]

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Li├Ęge.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

SOURCE: Hemogenyx Pharmaceuticals PLC

Back to newsroom
Back to Newsroom
Share by: